StockData
Organogenesis Holdings Inc. logo

Organogenesis Holdings Inc. (ORGO) company profile

ORGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 10/30
$0.81+0.01 (+1.06%)

Close on Nov 17, 2026Market cap $104.43MP/E –Yield –

About Organogenesis

Pharmaceutical Preparations, SIC 2834

Organogenesis Holdings Inc. develops, manufactures, and sells regenerative medicine solutions. The company operates across two primary commercial segments: Advanced Wound Care and Surgical & Sports Medicine. Its advanced wound care offerings include products such as Apligraf, Dermagraft, PuraPly, CYGNUS, VIA Matrix, Affinity, Novachor, NuShield, and SimpliMax, which treat acute and chronic wounds, including diabetic foot ulcers and venous leg ulcers. In the surgical and sports medicine segment, the company supplies products like PuraForce, NuShield, Cygnus Matrix, and PuraPly for soft tissue repair, tendon and ligament injuries, and open surgical wounds. Its customer base includes hospitals, outpatient wound care centers, government facilities, ambulatory surgery centers, and physician offices.

The company maintains its corporate headquarters and principal executive offices in Canton, Massachusetts. Its operations also include an additional manufacturing facility located in Smithfield, Rhode Island. Organogenesis conducts business within the United States, utilizing direct sales capabilities alongside independent sales agency networks to distribute its medical products to healthcare providers.

Summary of the business section of Organogenesis's latest annual report, written by StockData.

Company profile

Company

Legal name
Organogenesis Holdings Inc.
Headquarters
Canton, MA
Address
85 Dan Road 02021
Phone
(781) 575-0775
Employees
854, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
RSM US LLP, Boston, Massachusetts

Stock & identifiers

Ticker
ORGO
Exchange
Nasdaq
IPO date
Oct 11, 2016
Shares outstanding
129M, Jul 31, 2026
Public float
$299.40M, Jun 30, 2025
Filer category
Accelerated filer
SEC CIK
1661181
CUSIP
68621F102
ISIN
US68621F1021
FIGI
BBG00FGGD295
Share class FIGI
BBG00FGGD311
LEI
549300RLC2O821TU6941
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Gary S. GillheeneyPresident and CEO, Director4,323,398
Brian GrowChief Commercial Officer900,682
Robert CavorsiVice President, Strategy275,524
Patrick BilboChief Operating Officer1,128,312
Antonio S. MontecalvoVice President, Health Policy230,016
David FranciscoChief Financial Officer745,999
Lori FreedmanChief Admin. and Legal Officer1,023,643
Patrick McGuireChief Accounting Officer16,965
Michael Joseph DriscollDirector225,707
Arthur S. LeibowitzDirector291,014
Jon L. GiacominDirector241,026
Gilberto QuinteroDirector239,073
Prathyusha DuraibabuDirector247,047
Michele Ilene KorfinDirector239,073
Garrett LustigDirector125,742
Glenn H. NussdorfDirector11,748,560
Alan A. AdesDirector102,170,806

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$6.81M$15.18M$2.07M$69$120
FY2024$6.99M$12.48M$2.10M$67$114
FY2023$6.24M$10.49M$1.93M$85$115
FY2022$6.01M-$1.04M$1.30M$56$111
FY2021$4.43M$6.31M$1.28M$192$125
FY2020$2.54M$5.10M$975.08K$157$126

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryStock awardsOption awardsIncentive payOtherTotalvs. prior year
Gary S. Gillheeney, Sr.
President and Chief Executive Officer; Principal Executive Officer
$979.11K$2.83M$1.38M$1.54M$82.73K$6.81M-3%
David Francisco
Chief Financial Officer; Principal Financial Officer
$514.63K$660.73K$325.46K$445.47K$40.78K$1.99M-2%
Patrick Bilbo
Chief Operating Officer
$514.48K$736.67K$362.32K$441.38K$62.09K$2.12M-7%
Lori Freedman
Chief Administrative and Legal Officer
$518.84K$648.30K$319.42K$513.08K$43.24K$2.04M+2%
Brian Grow
Chief Commercial Officer
$485.12K$732.39K$360.24K$518.37K$47.37K$2.14M+2%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

SPAC offering

Type
SPAC (blank check) IPO of units
Final prospectus filed
Oct 11, 2016
Offer price
$10.00
Securities offered
30,000,000
Gross proceeds
$300.00M
Exchange
Nasdaq
First trading day
Dec 5, 2016
First-day close
$10.30+3.0%
Lock-up ends (est.)
Jun 3, 2017

“Each unit has an offering price of $10.00 and consists of one Class A ordinary share and one warrant.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had approximately 854 employees worldwide.”

Corporate history

Events identified from SEC filings

DateEventDetails
May 27, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 14, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Mar 12, 2019DelistingNotice of delisting from exchange (Form 25)
Mar 12, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 7, 2019Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 14, 2018DelistingNotice of delisting from exchange (Form 25)
Dec 12, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 11, 2018Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 11, 2018Auditor changeChange in certifying accountant (8-K Item 4.01)
Dec 10, 2018Name changeName changed from Avista Healthcare Public Acquisition Corp. to Organogenesis Holdings Inc.
Nov 5, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 30, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Aug 29, 2018MergerRegistration of securities for a merger or exchange offer (S-4)
Jan 9, 2018Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 22, 2017MergerRegistration of securities for a merger or exchange offer (S-4)
Oct 11, 2016IPOInitial public offering priced (424B4 prospectus)
Oct 5, 2016ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?